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Abstract: The evolutionary response to endemic infections with parasitic worms (helminth) was
the development of a distinct regulatory immune profile arising from the need to encapsulate the
helminths while simultaneously repairing tissue damage. According to the old friend’s hypothesis,
the diminished exposure to these parasites in the developed world has resulted in a dysregulated
immune response that contributes to the increased incidence of immune mediated diseases such as
Multiple Sclerosis (MS). Indeed, the global distribution of MS shows an inverse correlation to the
prevalence of helminth infection. On this basis, the possibility of treating MS with helminth infection
has been explored in animal models and phase 1 and 2 human clinical trials. However, the possibility
also exists that the individual immune modulatory molecules secreted by helminth parasites may
offer a more defined therapeutic strategy.
Keywords: multiple sclerosis; environmental factors; helminth parasites; old friend’s hypothesis;
immune modulation; innate immunity
1. Introduction
Multiple Sclerosis (MS) is an autoimmune demyelinating disease that can manifest as a wide
range of clinical signs and symptoms and present with varying severity. It is generally accepted
that a combination of individual genetic susceptibility and environmental factors contribute to the
development of autoimmune diseases like MS, although the relative contribution of each of these
factors is hotly debated [1,2].
Genome wide association studies (GWAS) of MS patients have identified over 100 genetic risk
loci. However, most of these exert only a modest influence on MS risk and contribute only 20–30% of
the perceived heritability of MS, suggesting that the remaining 70–80% of unexplained susceptibility is
affected by environmental factors [2–4]. Furthermore, in studies of identical twins where one develops
MS, only 25% of second twins developed the disease [5]. Such discordance between monozygotic twins
strongly supports a critical role for an environmental factor in the initiation of MS. However, perhaps
the most compelling evidence in this regard has been the rapid increase in the incidence rates of MS in
the developed world over recent years [6–9]. This rise far exceeds the rate of population evolution
and therefore implies either the removal of protective factors or the introduction of susceptibility
factors in the environment. Indeed, population migration studies indicate that the place of residence
in adolescence or early adulthood strongly influences a person’s subsequent risk of MS [10–13].
Identification of the possible environmental factors has been informed by the unusual geographic
distribution of the disease. The prevalence of MS increases with increasing latitude, such that higher
rates of incidence are found in high latitude regions [4,14]. MS is also more common in the developed
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world than the developing world [15]. Based on these epidemiological observations, several putative
environmental risk factors have been proposed such as low vitamin D, Epstein–Barr virus, sanitation
and smoking [4,15–17]. However, perhaps the most compelling environmental relationship is the
worldwide inverse correlation between infections with parasitic worms (helminths) and the incidence
of autoimmune disease [18].
Corroborating this hypothesis, longitudinal and migratory studies evaluating the prevalence of
MS in the French West Indies over a period of 20 years showed that increased MS incidence in the region
was associated with a significant reduction of parasite infections during the same time period [19].
More specifically, the prevalence of MS was reportedly significantly reduced once a critical threshold
(10%) of infection with the helminth Trichuris trichiura was exceeded in any given population [20].
The fact that administration of anti-helminth drugs resulted in increased MS activity [21], suggests
that helminths directly suppress autoimmune diseases and may be the protective environmental factor
against the development of MS.
2. Should We Reunite with Our Old Friends the Helminth Parasites?
The human immune system evolved to provide protection from a range of pathogenic
microorganisms (viruses, bacteria, fungi and protozoan). However, despite also being regarded
as pathogenic, the immune response to helminth parasites does not typically provide protection from
re-infection. Instead, most of these organisms are well tolerated by their human hosts, with infections
lasting for many years [22]. Moreover, infections are primarily asymptomatic and mortality is rare. It is
suggested that this phenomenon has occurred due to the long evolutionary coadaptation between these
parasites and man [23,24], through which helminth parasites have strongly influenced the evolution of
the human immune system. This is because infection was not associated with the onset of epidemics
but rather helminth parasites have been ubiquitous within human populations over millennia [23].
The canonical immune response to helminth parasite infection is the development of an
anti-inflammatory, type 2 immune response, characterised by the secretion of cytokines Interleukin
(IL)-4, IL-5, IL-9 and IL-13 [25–27], and the simultaneous suppression of pro-inflammatory T helper
(Th)-1 and Th17 responses [28]. Initially, it was thought that these type 2 cytokines were produced by
Th2 cells. However, several studies have demonstrated that the helminth-induced type 2 responses can
be generated in the absence of T cells [29] and have led to the recent identification of a non-redundant
role for type 2 innate lymphoid cells (ILC2) in the recognition and response to parasitic worms [30].
ILC2 secrete IL-4, IL-5, IL-13 and amphiregulin to combat helminth infection [31]. This switch towards
a type 2 immune response also leads to the inhibition of pro-inflammatory M1 macrophages and
dendritic cells (DCs) and, instead, the induction of an immature phenotype of dendritic cells (DC2s)
and an anti-inflammatory phenotype of macrophage (termed helminth-M2 macrophages) [32]. As the
parasite infection reaches chronicity, the differentiation of T-regulatory (Treg) populations is initiated.
These cells secrete regulatory cytokines, such as IL-10 and transforming growth factor-β (TGF-β) [33],
which further inhibit Th1 responses, and also regulate type 2 responses. This prevents the generation
of extensive tissue fibrosis, which would result from sustained wound healing activity mediated by
helminth-M2 macrophages and their products [34].
The outcome for the host is to create a balance in which the parasite is tolerated, and homeostasis
can be maintained. It is suggested that the Treg response is crucial for invoking specific immunological
tolerance. However, when damage does occur, a more physiological tolerance mechanism, including
the ability to repair the damage, is maintained by type 2 effector pathways [35].
This evolutionary development in immune responsiveness to infection with helminths has
resulted in compensatory adjustments to immune-related genes in human populations [36,37]. In fact,
it has been proposed that, in order for the human immune system to operate optimally, the presence of
helminth induced immunoregulatory networks are required [38]. Accordingly, in populations where
parasitic infections are no longer endemic, there is an increased likelihood of inappropriate immune
responsiveness to autoantigens, and the concomitant development of autoimmune/inflammatory
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diseases, such as MS. Consequently, many have asked the question of whether helminths should
be regarded as beneficial commensals and whether the re-introduction of these old friends may be
therapeutic in MS [7,39–43].
3. Worm Therapy: Proof-of-Principle in Experimental and Clinical Trials
3.1. Testing the Effectiveness of Helminth Infection in Animal Models of MS
The most widely used animal model of MS is experimental autoimmune encephalomyelitis
(EAE), which mimics several of the key clinical and pathological features of the human disease, such
as paralysis and demyelination. EAE studies have provided critical information on autoimmune
related central nervous system (CNS) damage, demyelination, presence of immunoglobulins in
CNS and cerebrospinal fluid, distribution of lesions and remyelination processes, and much of our
understanding of the likely pathological mechanisms in MS came from work using the EAE models.
EAE is actively induced in rodents via immunisation with a neuroantigen emulsified in adjuvant
(typically complete Freund’s adjuvant). The neuroantigen is typically a whole tissue homogenate (e.g.,
spinal cord), myelin protein (e.g., MOG, myelin oligodendrocyte glycoprotein), or purified myelin
peptide (e.g., MOG35–55, PLP139–151). The experimental choice of animal, neuroantigen and adjuvant
influences the outcome of EAE, which is quite variable (e.g., acute, relapsing, or chronic forms) [44].
After immunisation with the neuroantigen, there is typically an induction phase (0–10 days after
immunisation) during which the autoreactive T cells are activated and disseminate. This is followed by
the effector phase (10–30+ days after immunisation with neuroantigen) during which the autoreactive
T cells in the CNS activate microglia and macrophages, which subsequently damage myelin and other
CNS components. At this stage, signs of clinical disease, such as paresis and paralysis, are evident in
the animals.
Encouragingly, of the 12 studies reported to date (Table 1), in all but one case, infection of
rodents with helminth parasites protected the animals from EAE. The range of experimental design,
dosing, treatment schedules and choice of helminth (and thus tissue site being colonised) make it
challenging to determine a single specific mechanism of disease prevention. However, as expected
for a helminth infection, in all cases, there was an overall switch in the autoantigen specific immune
response from a pro-inflammatory Th1 and Th17 response towards a type 2 or Treg predominant
response. In the majority of cases, the worms were administered to animals prior to the induction
phase of disease (pre-induction), which, considering the parasite’s ability to suppress pro-inflammatory
immune responses, may simply reflect a suppression of the induction of immune responses to the
administered neuroantigen. Alternatively, it could also be considered that such timing for therapeutic
manipulation during EAE experiments best models the effect of preventive therapy for a new relapse
or episode in MS [15]. More persuasive is the demonstration that, when delivered during the effector
phase of the disease, the intestinal parasite H. polygyrus, mediated complete amelioration of the
clinical signs of disease within six days [45]. In contrast, infection with the blood fluke S. mansoni was
ineffective when delivered during the effector phase, despite showing efficacy when administered
during the pre-induction or induction phases [46]. This suggests that not every helminth will offer
beneficial effects and the choice of parasite may be the most critical factor in the development of
worm therapeutics.
3.2. Testing the Effectiveness of Helminth Infection in Human Trials
The first direct evidence that helminth infection could prevent MS came from a series of
observational studies beginning in 2007 [47]. This prospective investigation examined the clinical
status of 12 relapsing-remitting MS subjects who had naturally contracted gastrointestinal parasites
and compared them to a second cohort of demographically-matched MS patients without parasite
infection. Over a period of 4.5 years, the patients infected with helminth parasites had a dramatic and
sustained reduction in clinical, magnetic resonance imaging (MRI), and immunological parameters of
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MS activity, compared to the uninfected subjects. During the follow up study over the next 5–7 years,
one third of the patients infected with helminths developed severe gastrointestinal symptoms and
were treated to clear the helminth [21]. Unfortunately, elimination of the parasites in those patients
also resulted in a return of the clinical and MRI signs of disease to a level similar to that seen in the
patients who were not infected. This finding provided support for the notion that helminth infection
might be a useful therapeutic approach for the treatment of MS, and led to the initiation of several
clinical trials using live helminth infection in patients with MS (summarized in Table 2).
To date, all phase 1 studies have shown that treatment with the helminths is safe. Some, but not
all, have also shown promising effects on clinical outcomes, brain MRI measures. However, as efficacy
was not the primary outcome of these studies, these data should be interpreted with caution. Over the
last three years, two double-blinded, placebo-controlled phase 2 trials have been undertaken. One of
these is still ongoing (HINT2) and although the second (WIRMS) is completed; the results have not yet
been published. These studies will provide a comprehensive and meaningful outcome and determine
the future of live worm therapeutics.
Analysis of systemic immunological changes in MS patients therapeutically infected with
helminths reported a profile of beneficial immune modulation. A general increase in serum IL-4, IL-5
and IL-10 supported a helminth induced switch to Th2/Treg immune responses [48]. In addition, the
secretion of IFNγ from antigen stimulated T cells was significantly reduced, indicating a suppression
of autoantigen specific Th1 responses [49]. A similar outcome has been reported in patients with
inflammatory bowel disease and coeliac disease therapeutically infected with T. trichiura or hookworm,
respectively [50,51]. In both cases, during parasite infection, the clinical symptoms of immune
mediated disease abated in parallel with a decrease in IL-17 producing T cells. However, in these
particular disease indications, the immune modulation promoted by parasite infection also mediated
physiological changes to improve clinical symptoms. The accumulation of IL-22 producing T cells
in the intestinal mucosa of infected patients was suggested to promote intestinal mucus production
to reduce symptomatic colitis [50]. While similar relationships have not yet been investigated for
helminth infected MS patients, given the growing evidence for functional crosstalk between the gut
and the CNS, it is possible that intestinal immunological changes occurring in response to helminth
infection is causally related to a positive modulation of brain autoimmunity.
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Table 1. Studies reporting live helminth infection in animal models of Experimental Autoimmune Encephalomyelitis.
Animal Model a Helminth Treatment b




Schistosoma mansoni 5000–20,000 eggs i.p. ++ + - Polarisation of immune response to Th2 [46]
Schistosoma mansoni 5000–10,000 eggs i.p./s.c. ++ ++ - Increase in IL-4, reduction in Interferon (IFN)-γ [46]
MOG35-55C57BL/6 mice
Schistosoma mansoni 5000–10,000 eggs i.p./ s.c. ++ ++ - Increase in IL-4, reduction in IFN-γ [46]
Schistosoma mansoni 70 cercariae cutaneous ++ n.d. n.d. Reduction of Th1 pro-inflammatory cytokines [52]
Fasciola hepatica 10 metacercariae p.o. ++ n.d. n.d. Bystander attenuation of Th17 and Th1 responses bymeans of Transforming growth factor (TGF)-β [33]
Trichinella pseudospiralis 200 larvae p.o. ++ n.d. n.d. Strong Th2 responses; Th1 and Th17 responsessuppressed [53]
Taenia crassiceps 400 metacestodes i.p. +++ n.d. n.d. Anti-inflammatory cytokine environment leads toreduced T cell activation [54]
Heligmosomoides polygyrus 200 larvae p.o. n.d. n.d. ++ Reduction of IL-17A, IL-12 and promotion ofregulatory cytokines [55]
MBP-EAE in Lewis rats Strongyloides venezuelensis 4000 larvae s.c. - n.d. n.d. No effect on disease course; The host may be resistantto helminth infection [45]
Spinal cord homogenate
in Dark agouti (DA) rats
Trichinella spiralis larvae Multiple doses by gastric
inoculation 500 & 1000 ++ n.d. n.d.
Th2 response and regulatory response increase, also
increase in IL-10 [56]
Trichinella spiralia Larvae p.o. + ++ n.d. Th2 cytokine bias; anti-inflammatory responses likelydue to regulatory T cells [57]
a PLP, proteolipid protein; MOG, myelin oligodendrocyte glycoprotein; MBP, myelin basic protein; b p.o., oral administration; i.p., intra-peritoneal injection; s.c., sub-cutaneous injection;
c The effect of helminth treatment on EAE severity, depending on the time at which helminth was administered is indicated by the following symbols: -, no effect; +, mild; ++, moderate;
+++, strong; n.d., not done.
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Table 2. Human clinical trials of live helminth infection as a therapeutic for Multiple Sclerosis.
ClinicalTrialsgov a End Date Subjects b Helminth Treatment c Clinical Evaluation Parameters d Results Status e Ref.
HINT 1
NCT00645749 2011 5 RRMS
2500 TSO orally
2 weeks × 12 weeks
Number of new gadolinium
enhancing lesions on serial MRI
scans (monthly)
Treatment was safe. No adverse effects.
No. of lesions fell from 6.6 at baseline to 2.
Serum IL-4, IL-10 increased in 4 patients
C [48]
TRIMS-A 2010
NCT01006941 2011 10 RRMS
2,500 TSO orally
2 weeks × 12 weeks
No. of new or enlarging T2 lesions,
no. of Gd enhancing lesions, volume
of T2 lesions
Well tolerated; minor gastrointestinal
symptoms. No beneficial effect. C [58]
Charite safety study 2011 4 SPMS 2500 TSO orally2 weeks × 4 weeks
Immunological & clinical parameters
were assessed
Treatment was safe.
Lower Th1 & increase in Th2 (IL-4) C [49]
TRIOMS 2012
NCT01413243 2016 50 RRMS
2,500 TSO orally
2 weeks × 12 weeks
Number of new gadolinium
enhancing lesions on serial MRI




NCT01470521 2016 72 RRMS
25 live Necator americanus
dermally
Number of new gadolinium
enhancing lesions on serial MRI
scans (at month 9), change in
expanded disability status scale
Final results not released—expecting lower
number of lesions C [39]
HINT 2
NCT00645749 2017 18 RRMS
2,500 TSO orally
2 weeks × 10 months
Number of new gadolinium
enhancing lesions on serial MRI
scans (monthly)
Safety confirmed. Interim MRI and
immunological measures positive. O [15,60]
a Clinicaltrials.gov website provides details of study design and updates on study progress. (NCT = national clinical trial; HINT = helminth-induced immunomodulation therapy;
TRIMS-A = Trichuris suis ova therapy for multiple sclerosis—a safety study; TRIOMS = Trichuris suis ova in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome;
WIRMS = worms for immune regulation of multiple sclerosis). b The number and type of MS patients are listed (RRMS = relapsing-remitting MS; SPMS = secondary progressive MS).
c TSO, Trichuris suis OVA. d MRI, magnetic resonance imaging. e Study status is indicated by C (completed), O (Ongoing), T (Terminated).
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4. Translating to the Clinic: Worms or Molecules?
Collectively, the evidence gathered from natural endemic population studies, experimental animal
work and human trials clearly support the possibility that helminths could be used as a treatment
option for multiple sclerosis and provides a strong rationale that “worm therapy” is worth pursuing
for the prevention or treatment of autoimmune disease.
However, the use of live parasites is not optimal. The compliance of patients is predicted to be
generally poor, and this is largely attributable to negative attitudes associated with the concept of
being infected with live pathogens [61]. In addition, the intake of live parasites (and, in some cases,
the subsequent infection) has caused adverse side effects, at times even exacerbating pro-inflammatory
conditions, due to the parasite’s feeding and migratory activities [62,63].
The larval stages, which have been shown to be therapeutically beneficial in trials, must be
produced in a mammalian host [28], so the possibility of a large scale production in compliance with
good manufacturing practices (GMP) is limited and prohibits the mass scale production required
for a truly global therapeutic. There is also a significant risk of contamination with other human
pathogens. For example, the parasite N. americanus is harvested from the faeces of infected individuals.
The use of the pig whipworm, T. suis, does not circumvent this problem, as there is a transferral risk of
hepatitis E virus, which is often found in pigs and is pathogenic to humans [64]. Accordingly, the use
of pathogen-free pigs would be required to ensure the absence of such infectious contaminants [64,65].
Additionally, using T. suis as a therapeutic agent requires the frequent intake of 2500 eggs, a dosing
regimen with which many patients fail to comply. This is compounded with the fact that all ova might
not hatch into active juveniles, thereby reducing the impact of the dose. Thus, the selection of the right
helminth with the exact dosage and schedule of the treatment is difficult.
Finally, but most importantly, there is a lack of specificity with the use of live parasites.
In populations endemically infected with helminths, Th1 and/or Th17 immune responses are
compromised, which prevents the development of appropriate immune responses to bacterial/viral
pathogens and vaccination [66]. Thus, the patient is effectively immune-compromised, just as
he/she would be if prescribed immunosuppressive drugs. For individuals who are already immune
compromised (such as children, the elderly, and pregnant women), treatment regimens using live
helminth infections may be of greater risk than benefit [67–69].
A safer and more reliable alternative to live infection would be to identify the specific
immune-modulatory molecules produced by helminth parasites. This approach would allow the
precise mechanism(s) of action to be characterized, and their properties to be modified to increase
therapeutic efficacy. In addition, synthetic proteins can be easily manufactured to therapeutic standard,
and can be modified during synthesis into small molecule analogues to enhance stability, and to reduce
undesirable immunogenicity and toxicity.
Within their mammalian hosts, helminth parasites secrete and excrete a mixture of molecules.
These excretory/secretory (ES) products perform a number of biological functions to support the
parasite’s growth and reproduction, such as degradation of haemoglobin into essential nutrients
and cleavage of collagen to facilitate migration through tissues. However, the ES products from
many helminths also have the capacity to modulate host immune responses, analogous to live
infection [70–73]. Furthermore, the delivery of ES products from a number of different helminths
prevents or ameliorates the clinical signs of autoimmune disease in animal models of EAE (Table 3).
In these experiments, all of the ES products prevented the development of disease when delivered
during the pre-induction phase. Moreover, a strong protective effect was also observed when ES
(in two experiments) was administered at or after the induction phase of disease. Consistent with
the observation that intraperitoneal delivery of S. mansoni eggs to animals afforded protection from
EAE (Table 1), the administration of secreted egg antigens (SEA) derived from the same parasite also
suppressed the progression of disease (Table 3) [74].
Based on this evidence, a typical process for drug discovery would involve a rational search
through the contents of SEA to identify the key molecule that is mediating beneficial immune
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modulation to prevent disease development. However, SEA is the soluble products derived from
the homogenate of eggs and therefore contains numerous components that are naturally secreted
from eggs during infections, but also molecules that are normally held within the structure of the egg.
Proteomic analysis using two-dimensional electrophoresis of SEA has identified >1000 proteins [75];
thus, identifying the singular components that may be mediating protection from EAE presents a
challenging task.
The clinical signs of EAE were also reduced in mice treated with the ES derived from
Fasciola hepatica. Unlike SEA, this preparation contains only the products that are naturally secreted by
the adult worm and therefore is more likely to contain the proteins that are secreted during infection
and which interact with the cells of the host immune response. Furthermore, in contrast to the
complexity of SEA, proteomic analysis of F. hepatica ES has identified 160 proteins, 67% of which are
cysteine proteases [76].
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Table 3. Experimental studies assessing the protective effect of helminth soluble products in animal models of EAE.
Animal Model Helminth Treatment a
Time Point of Administration b





100 µg i.p. once a week for 4 weeks + ++ Th2 environment established. [74]
Trichuris suis SP
100 µg i.p. once a week for 4 weeks ++ n.d.
Unknown. In vitro suppression of pro-inflammatory
dendritic cells [77]
Trichuris spiralis SP
100 µg i.p. once a week for 4 weeks ++ n.d.
Unknown. In vitro suppression of pro-inflammatory
dendritic cells [77]
Trichuris suis ESP
250 µg i.p. alternate days over 22 days n.d. ++ Reduced number of splenic Th1 and Th17 cells [78]
F. hepatica ESP
Five or Six daily doses of 50 µg/dose i.p. + ++ Production of innate type 2 cytokines IL-5 and IL-33. [79]
Taenia Crassiceps ESP
250 µg i.p. alternate days × 7 times n.d. +++
Induction of Th2. Suppression of Tumour Necrosis
Factor (TNF) and IL-17. Redirected cell migration




Trichinella spiralis larvae ESP
Multiple doses of soluble products i.p. ++ n.d.
Strong Th2-type response and increased proportion of
CD4+CD25-Foxp3+ regulatory cells [81]
a SEA, Schistosome egg antigen; SP, secretory products; ESP, excretory/secretory products; i.p., intra-peritoneal injection. b The effect of helminth treatment on EAE severity, depending on
the time at which helminth was administered is indicated by the following symbols: +, mild; ++, moderate; n.d., not done.
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5. The Peptide FhHDM-1, Secreted by Fasciola hepatica, Shows Therapeutic Efficacy in EAE
F. hepatica, commonly known as the liver fluke, has adapted to long-term survival within its
mammalian hosts, living up to 20 years in some instances [82,83]. Additionally, F. hepatica exhibits a
widespread geographical distribution, and infects the greatest variety of mammals of all helminth
parasites [84,85]. Not only does this imply a superior adaptation, as compared to other helminth
parasites, such as N. Americanus and T. suis, which have adapted to infect only a single host, but
it also suggests that Fasciola parasites have evolved universal processes of invasion, virulence and
immune modulation.
The infection pathway of F. hepatica begins within the mammalian host after the ingestion of
metacercariae, which are the encysted larval form of the worm (Figure 1). Upon reaching the acidic
environment of the gastrointestinal tract, immature flukes hatch, and these newly excysted juvenile
(NEJ) flukes migrate through the gut wall to enter the peritoneal cavity. The NEJ flukes continue
to burrow through to the liver, reaching the bile ducts 10–12 weeks after ingestion. Within the bile
ducts, the NEJ flukes mature into adult forms, whose primary activities are feeding on blood by
puncturing holes in the bile duct wall, and production of eggs [82]. The mature adults are obligate
blood feeders and secrete copious amounts of cysteine proteases (FhCL) to effectively digest blood
proteins, particularly haemoglobin, to provide sufficient nutrients required for egg production [86].
Related to this activity is the production of the anti-oxidant peroxiredoxin (FhPrx), which detoxifies the
reactive oxygen generated by cellular metabolism [86,87], and the production of FhHDM-1, a peptide
that interacts with heme, a toxic by product of haemoglobin digestion [88]. In addition to these
activities to support the parasite’s life cycle, these three proteins have also been shown to act as
potent immune modulators, specifically inhibiting the activation of pro-inflammatory innate immune
responses [89–93].
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Figure 1. Fasciola hepatica lifecycle. Graphical representation of the F. hepatica lifecycle (adapted from 
[82]). (A1) parasite excyst in the intestine of the mammalian host, releasing newly excysted juveniles 
(NEJ) that migrate across the intestinal wall, through the peritoneal cavity to the liver (A2). NEJ 
migrate through the liver parenchyma, increasing in size to juvenile flukes as they migrate into the 
bile ducts (A3), where they grow and develop into fully mature adults (A4); (B1) eggs are released in 
the faeces and develop on vegetation; (B2) a single miracidium hatches from each embryonated egg 
and then (B3) infects the intermediate snail host (Galba truncatula); (B4) within the snail, the parasite 
develops through the sporocyst, rediae and cercariae lifecycle stages. Cercariae are released from 
the snail and (B5) encyst on vegetation as dormant metacercariae, which are subsequently ingested 
by the definitive host. 
6. Conclusions 
The studies discussed here represent a significant body of evidence that proteins secreted by 
helminth parasites offer a unique resource for the discovery of anti-inflammatory drugs. The specific 
finding that a single parasite secreted protein, FhHDM-1, can suppress the pathology associated 
with EAE, although preliminary, suggests that understanding the mode of action of this parasite 
protein may provide a novel starting point in the development of safe effective drugs for treatment 
of human MS. The efficacy of parasite-derived molecules has been fine-tuned over millennia of 
co-evolution with humans, suggesting that the pharmacological activity of these proteins has 
already been optimized over time by nature. Therefore, exploiting the excretory secretory products 
from helminth parasites offers the potential for drug treatments that are far superior to current 
biologicals whose widespread use is limited by a lack of specificity and a range of adverse side 
effects. 
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Figure 1. Fasciola hepatic l fecycle. Graphical representation of the F. h patica lifecycle (adapted
from [82]). (A1) parasite excyst in the intestine of the mammalian host, releasing newly excysted
juveniles (NEJ) that migrate ac oss the i testinal wall, through the peritoneal cavity to the liver (A2).
NEJ migrate through the liver parenchyma, increasing in size to juvenile flukes as they migrate into the
bile ducts (A3), where they row and develop into fully matur adults (A4); (B1) eggs are released in
the faeces and develop on vegetation; (B2) a single miracidium hatches from each embryonated egg
and then (B3) infects the intermediate snail host (Galba truncatula); (B4) within the snail, the parasite
develops through the sporocyst, rediae and cercariae lifecycle stages. Cercariae are released from the
snail and (B5) encyst on vegetation as dormant metacercariae, which are subsequently ingested by the
definitive host.
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Considering their capacity to alter inflammatory immune responses, we assessed the therapeutic
efficacy of recombinant forms of the three most abundant molecules of F. hepatica ES, FhPrx, FhCL1
and FhHDM-1 in an animal model of relapsing remitting EAE. Despite their evident immune
modulating activity, neither FhPrx (Donnelly et al., unpublished data) nor FhCL1 [94] prevented
disease development. However, a short time course of treatment with FhHDM-1 significantly reduced
the clinical signs of EAE [94], which was associated with the absence of immune cell infiltrates into the
CNS. These observations suggested that, within the ES of the adult F. hepatica, FhHDM-1 may be the
sole molecule with potential as an immune therapeutic.
Unexpectedly, FhHDM-1 treatment of mice did not alter the profile of cytokines produced by
T cells in response to autoantigen. Unlike infection and the administration of ES, Th1 cytokines were
evident and there was no significant switch to a type 2 immune response. However, after parenteral
administration, the FhHDM-1 peptide interacted with macrophages and reduced their capacity to
secrete pro-inflammatory cytokines. Thus, it has been hypothesized that the inhibition of innate
pro-inflammatory immune responses, which are central to the development of autoimmunity in
EAE and MS, prevented the trafficking of autoreactive lymphocytes from the periphery to the site of
autoimmunity and thus prevented tissue destruction.
6. Conclusions
The studies discussed here represent a significant body of evidence that proteins secreted by
helminth parasites offer a unique resource for the discovery of anti-inflammatory drugs. The specific
finding that a single parasite secreted protein, FhHDM-1, can suppress the pathology associated with
EAE, although preliminary, suggests that understanding the mode of action of this parasite protein
may provide a novel starting point in the development of safe effective drugs for treatment of human
MS. The efficacy of parasite-derived molecules has been fine-tuned over millennia of co-evolution with
humans, suggesting that the pharmacological activity of these proteins has already been optimized
over time by nature. Therefore, exploiting the excretory secretory products from helminth parasites
offers the potential for drug treatments that are far superior to current biologicals whose widespread
use is limited by a lack of specificity and a range of adverse side effects.
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